In a randomized trial, none of over 5,000 young women and girls in South Africa and Uganda who received lenacapavir injections contracted HIV.
"If these injections can be widely distributed at low cost, it would dramatically reduce the risk of new HIV infections worldwide," said Sarah Palmer, a medical expert.
The trial for lenacapavir, funded by Gilead Sciences, proved more effective than daily pills in preventing HIV, leading to its early termination and global distribution potential.
[
Collection
]
[
|
...
]